top of page
The Professional Network for Healthcare Experts
Amneal completes $750 million Kashiv BioSciences acquisition to create integrated biosimilars platform
The completed transaction combines Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial infrastructure, giving the company end-to-end control across biosimilar development, production and commercialisation.
nuaxia
5 days ago3 min read
FDA approves Reditux as rituximab biosimilar for B-cell malignancies and autoimmune diseases
The approval adds another US biosimilar option for rituximab-treated conditions, including non-Hodgkin lymphoma and chronic lymphocytic leukaemia, although commercial availability and pricing have not yet been confirmed.
nuaxia
Aug 62 min read
FDA Approves Accord BioPharma's ENNUMO Biosimilar to Neulasta
The approval expands Accord BioPharma's oncology supportive care portfolio, making it the only US company to offer two pegfilgrastim biosimilars alongside a filgrastim biosimilar.
nuaxia
Jul 102 min read
bottom of page